Collegium Pharmaceutical, Inc. COLL Symproic — Thereafter
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept coll:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s symproic — thereafter.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s symproic — thereafter?
- Collegium Pharmaceutical, Inc. (COLL) reported symproic — thereafter of $6.07M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s symproic — thereafter changed year-over-year?
- Collegium Pharmaceutical, Inc.'s symproic — thereafter decreased by 54.5% year-over-year, from $13.36M to $6.07M.
- What does symproic — thereafter mean?
- This metric represents the aggregate financial obligations or projected cash flows associated with the Symproic product line for periods extending beyond the standard five-year forecast horizon. It provides investors with visibility into the long-term tail revenue or cost profile of this specific pharmaceutical asset. Understanding these future commitments is essential for assessing the terminal value and long-term sustainability of the product segment.